Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...8384858687888990919293...401402»
  • ||||||||||  Journal:  The transcription regulator ATF4 is a mediator of skeletal muscle aging. (Pubmed Central) -  Nov 27, 2023   
    Furthermore, ATF4 mKO muscles are protected from some of the transcriptional changes characteristic of normal muscle aging (repression of certain anabolic mRNAs and induction of certain senescence-associated mRNAs), and ATF4 mKO muscles exhibit altered turnover of several proteins with important roles in skeletal muscle structure and metabolism. Collectively, these data suggest ATF4 as an essential mediator of skeletal muscle aging and provide new insight into a degenerative process that impairs the health and quality of life of many older adults.
  • ||||||||||  Journal:  Muscle atrophy in CKD: A historical perspective of advancements in its understanding. (Pubmed Central) -  Nov 27, 2023   
    The protein catabolism-inducing actions of metabolic acidosis, inflammation, insulin resistance, endocrine disorders and uremic toxins were progressively identified. Continued research to understand the interactions of inflammation, anabolic resistance, mitochondrial dysfunction, exercise, and nutrition on muscle protein turnover in patients with CKD will hopefully accelerate discoveries and treatments to ameliorate muscle wasting as well as the progression of CKD.
  • ||||||||||  Trial initiation date:  The Sarcopenia Study (clinicaltrials.gov) -  Nov 27, 2023   
    P=N/A,  N=80, Not yet recruiting, 
    Continued research to understand the interactions of inflammation, anabolic resistance, mitochondrial dysfunction, exercise, and nutrition on muscle protein turnover in patients with CKD will hopefully accelerate discoveries and treatments to ameliorate muscle wasting as well as the progression of CKD. Initiation date: Jun 2023 --> Nov 2023
  • ||||||||||  Trial completion date, Trial primary completion date:  Sarcopenia, Fall and Osteoporosis in Chronic Kidney Disease (clinicaltrials.gov) -  Nov 26, 2023   
    P=N/A,  N=140, Recruiting, 
    Initiation date: Jun 2023 --> Nov 2023 Trial completion date: Apr 2024 --> Jan 2024 | Trial primary completion date: Apr 2024 --> Jan 2024
  • ||||||||||  Review, Journal:  Transjugular Intrahepatic Portosystemic Shunt Placement: Effects on Nutritional Status in Cirrhotic Patients. (Pubmed Central) -  Nov 25, 2023   
    These modifications of the nutritional status, even more pronounced in sarcopenic patients before TIPS, have been associated with an amelioration of cognitive impairment after TIPS as well as with an increase in the survival rate. The aim of this paper is to provide an overview of the effects of TIPS placement on nutritional status in cirrhosis focusing on its pathophysiological mechanisms and its relationship with liver-related outcomes.
  • ||||||||||  Biomarker, Review, Journal:  Adipokines in Rheumatoid Arthritis: Emerging Biomarkers and Therapeutic Targets. (Pubmed Central) -  Nov 25, 2023   
    In addition, it explores the emerging role of adipomyokines, specifically irisin and myostatin, in the pathogenesis of RA and their potential as therapeutic targets. We discuss the therapeutic implications of targeting adipokines and adipomyokines in RA management and highlight the challenges and future directions for research in this field.
  • ||||||||||  Journal:  Association between Chronic Kidney Disease and Dynapenia in Elderly Koreans. (Pubmed Central) -  Nov 24, 2023   
    Additionally, the prevalence of dynapenia increased significantly as the stage of CKD increased (normal, stage 2, and stage 3-5: 18.5%, 20.8%, and 32.3% in men and 27.5%, 34.4%, and 46.1% in women, respectively). Thus, CKD is significantly related to dynapenia, especially in women, when stratified by sex.
  • ||||||||||  Journal:  Amino acids and cancer: potential for therapies? (Pubmed Central) -  Nov 24, 2023   
    We found little evidence demonstrating clinical benefits regarding individual or combined amino acid supplementation. Still, it is unclear how the use, dose, and specificity for different types of cancer should be prescribed or at what stage of treatment amino acids should be prescribed.
  • ||||||||||  Journal:  Sarcopenia is a predictor of patient death in acute ischemic stroke. (Pubmed Central) -  Nov 24, 2023   
    Still, it is unclear how the use, dose, and specificity for different types of cancer should be prescribed or at what stage of treatment amino acids should be prescribed. Masseter muscle area is an independent predictor of mortality in patients with AIS.
  • ||||||||||  Preclinical, Journal:  Mass Spectrometry-Based Multiomics Identifies Metabolic Signatures of Sarcopenia in Rhesus Monkey Skeletal Muscle. (Pubmed Central) -  Nov 22, 2023   
    Pathway analysis of age-responsive proteins and metabolites revealed changes in muscle structure and contraction as well as lipid, carbohydrate, and purine metabolism. Together, this study discovers new metabolic signatures and offers new insights into the molecular mechanisms underlying sarcopenia for the evaluation and monitoring of a therapeutic treatment of sarcopenia.
  • ||||||||||  Journal:  Association of Diet Quality with Hand Grip Strength Weakness and Asymmetry in A Multi-ethnic Asian Cohort. (Pubmed Central) -  Nov 22, 2023   
    Among the different components of DQI-I, only dietary adequacy was significantly associated with higher HGS (p-trend<0.001) and lower odds for both HGS weakness and asymmetry (p-trend=0.006). Our findings support that DQI-I, an indicator of overall diet quality, can be used to provide dietary guidelines for prevention and management of muscle wasting, sarcopenia, and frailty.
  • ||||||||||  Review, Journal:  Exercise rehabilitation to treat sarcopenia in pediatric transplant populations. (Pubmed Central) -  Nov 22, 2023   
    Studies that include body composition measurements in response to exercise are needed. Special considerations for the development of RE programs in pediatrics Tx populations are safety, supervision, engagement through family/peer involvement and incorporation of game/play-based elements.
  • ||||||||||  Sarcopenia is a Predictor of Post-Radiation Pathologic Vertebral Compression Fracture and Overall Survival (OrthoLive, West Hall) -  Nov 22, 2023 - Abstract #AAOS2024AAOS_255;    
    Its additive discriminatory value for predictive models of pathologic VCF and overall survival should be further evaluated. As sarcopenia can be opportunistically diagnosed on regularly available cancer surveillance CT, it has the potential for widespread adoption to enhance fracture risk stratification and treatment decision making.
  • ||||||||||  Journal:  GDF5: a therapeutic candidate for combating sarcopenia (Pubmed Central) -  Nov 21, 2023   
    In this context, our team develop therapeutic approaches based on the GDF5 protein to counteract the loss of muscle mass and function in various pathological conditions, including sarcopenia. After deciphering one of the molecular mechanisms governing GDF5 expression, we have demonstrated the therapeutic potential of this protein in the preservation of muscle mass and strength in aged mice.
  • ||||||||||  Retrospective data, Journal:  Clinical significance of sarcopenia in patients undergoing treatment for gastric cancer. (Pubmed Central) -  Nov 21, 2023   
    After deciphering one of the molecular mechanisms governing GDF5 expression, we have demonstrated the therapeutic potential of this protein in the preservation of muscle mass and strength in aged mice. In patients undergoing treatment for gastric cancer, sarcopenia increases postoperative complications and prolongs hospital and intensive care stays during the treatment process.
  • ||||||||||  Journal:  Prevalence of sarcopenia components and associated socioeconomic factors among older adults living in rural areas in the state of Cear (Pubmed Central) -  Nov 21, 2023   
    We tested for associations between sociodemographic characteristics and lifestyle habits and the components of sarcopenia. The logistic regression produced the following i) prevalence of low MS was higher among men, individuals aged >69 years, and in those not working at the time of the study; ii) the prevalence of low MMI was higher in individuals aged >69 years, those not living with a spouse, and those with an inadequate level of physical activity; iii) the prevalence of slow GS was higher in individuals aged >69 years, those who had lived in rural areas for less than 30 years, and those not working at the time of the study.
  • ||||||||||  Review, Journal:  Current and investigational medications for the treatment of sarcopenia. (Pubmed Central) -  Nov 21, 2023   
    Although some drugs have been effective in improving muscle mass and/or strength, this was not translated into clinically relevant improvements on physical performance. Finally, some promising molecules investigated in on-going clinical trials and in pre-clinical phase were summarized, including apelin and irisin.
  • ||||||||||  Journal:  Metabolic complications of obesity in children and adolescents. (Pubmed Central) -  Nov 21, 2023   
    These tests facilitate timely intervention by identifying high-risk groups for metabolic complications. Early detection and intervention through comprehensive health screening are critical to mitigate long-term complications of childhood obesity.
  • ||||||||||  Preclinical, Journal:  Sarcopenia of the longitudinal tongue muscles in rats. (Pubmed Central) -  Nov 20, 2023   
    We observed a robust ~30% loss of longitudinal specific force, with reductions in overall longitudinal muscle fiber CSA and specific atrophy of type IIx/IIb fibers. It will be important to investigate the mechanistic underpinnings of hypoglossal motor neuron death and tongue muscle weakness to eventually provide therapies for age-associated lingual dysfunctions.